

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**  
**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT**  
**RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR)**  
**OBTAINS HALAL DECREE IN INDONESIA**

This announcement is made by CanSino Biologics Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company is pleased to announce that, the Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (trade name: Convidecia<sup>®</sup>) developed by the Group has obtained Halal Decree by the Assessment Institute for Foods, Drugs and Cosmetics of Majelis Ulama Indonesia (LPPOM MUI).

Indonesia has the largest Muslim population in the world, with around 87% of its population practicing Islam. Pursuant to the public data, Indonesia has a total population of approximately 278 million, ranking the fourth largest population in the world in 2022. According to relevant regulations of Indonesia government, pharmaceutical products in Indonesia market shall be certified by Halal Product Assurance Body (BPJPH) to obtain the Halal Decree. The Halal Decree signifies that Convidecia<sup>®</sup> has gained access to the globally recognized Muslim market, which is conducive to the progress of the Company's internationalization.

Convidecia<sup>®</sup> is developed based on the viral vector platform of the Company. Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air<sup>®</sup>), TB Booster and Recombinant Zoster Vaccine are also developed based on the same technology platform. These vaccines have the potential to obtain Halal Decree in the future, which will enable the Company to further open the market in Muslim countries and regions.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, August 16, 2023

*As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU, Dr. Dongxu QIU and Ms. Jing WANG as executive directors, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*